CHINARES PHARMA (03320): Kunyu Pharmaceutical Group's net profit attributable to the parent in the first half of the year was approximately 198 million yuan, a decrease of 26.88% year-on-year.
China Resources Pharmaceutical Group (03320) announced Kunyu Pharmaceutical Group's performance in the first half of 2025, with total operating income of approximately 3.351 billion yuan.
CHINARES PHARMA (03320) announced Kunyu Pharmaceutical Group's performance in the first half of 2025, with total operating income of approximately 3.351 billion yuan, a decrease of 11.68% year-on-year; the net profit attributable to shareholders of the listed company was approximately 198 million yuan, a decrease of 26.88% year-on-year; basic earnings per share was 0.26 yuan.
Related Articles
US Stock Market Move | Q2 performance exceeds expectations, Nu Holdings (NU.US) increases by over 11%.
US Stock Market Move | CECEP Solar Energy, a concept stock of photovoltaic industry, has surged. Daqo New Energy Corp Sponsored ADR (DQ.US) rose more than 7%.
US Stock Market Move | Meta Platforms (META.US) rose nearly 2%, hitting a new all-time high and surpassing a total market value of over $2 trillion for the first time.
US Stock Market Move | Q2 performance exceeds expectations, Nu Holdings (NU.US) increases by over 11%.
US Stock Market Move | CECEP Solar Energy, a concept stock of photovoltaic industry, has surged. Daqo New Energy Corp Sponsored ADR (DQ.US) rose more than 7%.
US Stock Market Move | Meta Platforms (META.US) rose nearly 2%, hitting a new all-time high and surpassing a total market value of over $2 trillion for the first time.
RECOMMEND
Trump Administration Explores Government Equity Investment in Intel; Shares Soar Nearly 9%
15/08/2025
Inflation “Off the Charts”: U.S. July Producer Prices Surge 0.9% Month-on-Month, 3.3% Year-on-Year
15/08/2025
World Humanoid Robot Games Debut with Competitions in Soccer, Combat, Dance, and More
15/08/2025
